A circulating tumor DNA liquid biopsy can predict the likelihood of early disease progression among patients treated with chimeric antigen receptor T-cell therapy for advanced multiple myeloma, study results showed.
The noninvasive tool could be used to quantify a patient’s disease burden, according to investigators who presented findings at Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR.
Multiple myeloma is difficult to treat due to heterogeneity of genomic aberrations and treatment responses, according to Hitomi Hosoya, MD, PhD, research fellow in
